At the end of the latest market close, ImmunoPrecise Antibodies Ltd. (IPA) was valued at $5.59. In that particular session, Stock kicked-off at the price of $5.16 while reaching the peak value of $5.59 and lowest value recorded on the day was $5.13. The stock current value is $10.84.
Recently in News on July 22, 2021, ImmunoPrecise’s PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays. IPA publishes its scientific paper “Cornering an Ever-Evolving Coronavirus: TATX-03, a Fully Human, Synergistic, Multi-Antibody Cocktail Targeting the SARS-CoV-2 Spike Protein with in vivo Efficacy” on bioRxiv. You can read further details here
ImmunoPrecise Antibodies Ltd. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $19.00 on 02/19/21, with the lowest value was $5.05 for the same time period, recorded on 07/19/21.
ImmunoPrecise Antibodies Ltd. (IPA) full year performance was 15.98%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ImmunoPrecise Antibodies Ltd. shares are logging -67.47% during the 52-week period from high price, and 126.54% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $4.79 and $33.34.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 23961747 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the ImmunoPrecise Antibodies Ltd. (IPA) recorded performance in the market was -62.61%, having the revenues showcasing -42.90% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 106.65M.
Market experts do have their say about ImmunoPrecise Antibodies Ltd. (IPA)
During the last month, 0 analysts gave the ImmunoPrecise Antibodies Ltd. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 8.62, with a change in the price was noted -4.59. In a similar fashion, ImmunoPrecise Antibodies Ltd. posted a movement of -34.69% for the period of last 100 days, recording 190,171 in trading volumes.
Technical breakdown of ImmunoPrecise Antibodies Ltd. (IPA)
Raw Stochastic average of ImmunoPrecise Antibodies Ltd. in the period of last 50 days is set at 92.29%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 92.29%. In the last 20 days, the company’s Stochastic %K was 44.52% and its Stochastic %D was recorded 23.12%.
Bearing in mind the latest performance of ImmunoPrecise Antibodies Ltd., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -62.61%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -65.87%, alongside a boost of 15.98% for the period of the last 12 months. The shares increased approximately by 0.54% in the 7-day charts and went up by -13.06% in the period of the last 30 days. Common stock shares were lifted by -42.90% during last recorded quarter.